Risk Assessment Integrated QbD Approach for Development of Optimized Bicontinuous Mucoadhesive Limicubes for Oral Delivery of Rosuvastatin
- 90 Downloads
Statins are widely prescribed for hyperlipidemia, cancer, and Alzheimer’s disease but are facing some inherent challenges such as low solubility and drug loading, higher hepatic metabolism, as well as instability at gastric pH. So, relatively higher circulating dose, required for exerting the therapeutic benefits, leads to dose-mediated severe toxicity. Furthermore, due to low biocompatibility, high toxicity, and other regulatory caveats such as product conformity, reproducibility, and stability of conventional formulations as well as preferentially higher bioabsorption of lipids in their favorable cuboidal geometry, enhancement in in vivo biopharmaceutical performance of Rosuvastatin could be well manifested in Quality by Design (QbD) integrated cuboidal-shaped mucoadhesive microcrystalline delivery systems (Limicubes). Here, quality-target-product-profile (QTPPs), critical quality attributes (CQAs), Ishikawa fishbone diagram, and integration of risk management through risk assessment matrix for failure mode and effects analysis (FMEA) followed by processing of Plackett-Burman design matrix using different statistical test for the first time established an approach to substantiate the claims that controlling levels of only these three screened out independent process variables, i.e., Monoolein (B = 800–1100 μL), Poloxamer (C = 150–200 mg), and stirring speed (F = 700–1000 rpm) were statistically significant to modulate and improve the biopharmaceutical performance affecting key attributes, viz., average particle size (Y1 = 1.40–2.70 μ), entrapment efficiency (Y2 = 62.60–88.80%), and drug loading (Y3 = 0.817–1.15%), in QbD-enabled process. The optimal performance of developed Limicubes exhibited an average particle size of 1.8 ± 0.2 μ, entrapment efficiency 80.32 ± 2.88%, and drug loading 0.93 ± 0.08% at the level of 1100 μL (+ 1), 200 mg (+ 1), and 700 rpm (− 1) for Monoolein, Poloxamer, and stirring speed, respectively.
KEY WORDSQbD Risk assessment Limicubes Plackett-Burman Optimization
The authors are thankful to the Department of Pharmaceutics, School of Pharmaceutical Education and Research (formerly Faculty of Pharmacy), Jamia Hamdard, New Delhi, India for providing all instrument facilities required for carrying out research effectively.
Compliance with Ethical Standards
Conflict of interest
The authors report no conflicts of interest.
- 1.Beg S, Jain S, Kushwah V, Bhatti GK, Sandhu PS, Katare OP, et al. Novel surface-engineered solid lipid nanoparticles of Rosuvastatin calcium for low-density lipoprotein-receptor targeting: a quality by design-driven perspective. Nanomedicine. 2017;12(4):333–56. https://doi.org/10.2217/nnm-2016-0336.CrossRefPubMedGoogle Scholar
- 5.Glycerol monooleate (gmo)—manufacturing plant, detailed project report, profile, business plan, industry trends, market research, survey, manufacturing process, machinery, raw materials, feasibility study, investment opportunities, cost and revenue. http://www.npcs.in/profile-project-reports/profile/1242/glycerol-monooleate-gmo-manufacturing-plant-detailed-project-report-profile-business-plan-industry-trends-market-research-survey-manufacturing-process-machinery-raw-materials-feasibility-study-investment-opportunities-cost-revenue.html (accessed on 18/09/2017).Google Scholar
- 7.Seddon JM and Templer RH. Polymorphism of lipid-water systems. In: Lipowsky R, Sackmann E, editor. Structure and dynamics of membranes: I. from cells to vesicles/II. Generic and specific interactions. Amsterdam: Elsevier; 1995. p. 97–160.Google Scholar
- 12.Collings PJ, Hird M. Introduction to a special phase of matter. In: Collings PJ, Hird M, editors. Introduction to liquid crystals: chemistry and physics, vol. 1: CRC Press; 1997. p. 1–16.Google Scholar
- 13.Collings PJ and Hird M. Lyotropic liquid crystals—anisotropic solutions. In: Collings PJ and Hird M, editors, Introduction to liquid crystals: chemistry and physics. CRC Press; 1997. 7:135–148.Google Scholar
- 14.Boyd BJ. Controlled release from cubic liquid-crystalline particles (cubosome). In: Lynch ML, Spicer PT, editors, Bicontinuous liquid crystals. CRC press; 2005. 10:286–303.Google Scholar
- 16.Wang TY, Liu M, Portincasa P, Wang DQH. New insights into the molecular mechanism of intestinal fatty acid absorption. Eur J Clin Investig. 2013;43(11):1203–23.Google Scholar
- 18.Edward RR, Innes JK, Marino LV, Calder PC. Influence of different intravenous lipid emulsions on growth, development and laboratory and clinical outcomes in hospitalised paediatric patients: a systematic review. Clin Nutr. 2017; https://doi.org/10.1016/j.clnu.2017.07.003.
- 20.Newton MJ, Harjot K. Flunarizine dihydrochloride nanoemulsion for migraine nasal drug delivery: fabrication, characterization and in vitro study. Drug Deliv Lett. 2016;6(2):104–12.Google Scholar
- 21.Kawish SM, Ahmed S, Gull A, Aslam M, Pandit J, Aqil M, et al. Development of Nabumetone loaded lipid nano-scaffold for the effective oral delivery; optimization, characterization, drug release and pharmacodynamic study. J Mol Liq. 2017;231:514–22. https://doi.org/10.1016/j.molliq.2017.01.107.CrossRefGoogle Scholar
- 22.Brito Oliveira TC, Molina CV, Netto FM, Pinho SC. Encapsulation of betacarotene in lipid microparticles stabilized with hydrolyzed soy protein isolate: production parameters, alpha tocopherol coencapsulation and stability under stress conditions. J Food Sci. 2017;82(3):659–69. https://doi.org/10.1111/1750-3841.13642.CrossRefPubMedGoogle Scholar
- 23.Rao Z, Si L, Guan Y, Pan H, Qiu J, Li G. Inhibitive effect of Cremophor RH40 or Tween 80-based self-microemulsiflying drug delivery system on cytochrome P450 3A enzymes in murine hepatocytes. J Huazhong Univ Sci Technolog Med Sci. 2010;30(5):562–8. https://doi.org/10.1007/s11596-010-0543-0.CrossRefPubMedGoogle Scholar
- 26.Beg S, Sharma G, Thanki K, Jain S, Katare O, Singh B. Positively charged self-Nano emulsifying oily formulations of Olmesartan medoxomil: systematic development, in vitro, ex vivo and in vivo evaluation. Int J Pharm. 2015;493(1):466–82. https://doi.org/10.1016/j.ijpharm.2015.07.048.CrossRefPubMedGoogle Scholar
- 27.Kothari BH, Fahmy R, Claycamp HG, Moore CM, Chatterjee S, Hoag SWA. Systematic approach of employing quality by design principles: risk assessment and design of experiments to demonstrate process understanding and identify the critical process parameters for coating of the Ethylcellulose pseudolatex dispersion using non-conventional fluid bed process. AAPS PharmSciTech. 2017;18(4):1135–57. https://doi.org/10.1208/s12249-016-0569-0.CrossRefPubMedGoogle Scholar
- 28.Singh B, Kaur A, Dhiman S, Garg B, Khurana RK, Beg S. QbD-enabled development of novel stimuli-responsive gastroretentive systems of Acyclovir for improved patient compliance and biopharmaceutical performance. AAPS PharmSciTech. 2016;17(2):454–65. https://doi.org/10.1208/s12249-015-0367-0.CrossRefPubMedGoogle Scholar
- 30.Akhtar N, Verma A, Pathak K. Feasibility of binary composition in development of nanoethosomal glycolic vesicles of triamcinolone acetonide using Box-behnken design: in vitro and ex vivo characterization. Artif Cells Nanomed Biotechnol. 2017;45(6):1123–31. https://doi.org/10.1080/21691401.2016.1202261.CrossRefGoogle Scholar
- 31.Nguyen TH, Hanley T, Porter CJ, Boyd BJ. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration. J Control Release. 2011;153(2):180–6. https://doi.org/10.1016/j.jconrel.2011.03.033.CrossRefPubMedGoogle Scholar
- 32.Qadri GR, Ahad A, Aqil M, Imam SS, Ali A. Invasomes of Isradipine for enhanced transdermal delivery against hypertension: formulation, characterization, and in vivo pharmacodynamic study. Artif Cells Nanomed Biotechnol. 2017;45(1):139–45. https://doi.org/10.3109/21691401.2016.1138486.CrossRefPubMedGoogle Scholar
- 33.Gomes GS, Maciel TR, Piegas EM, Michels LR, Colomé LM, Freddo RJ, et al. Optimization of curcuma oil/quinine-loaded nanocapsules for malaria treatment. AAPS PharmSciTech. 2017; https://doi.org/10.1208/s12249-017-0854-6.
- 35.Yadav NK, Nanda S, Sharma G, Katare OP. Systematically optimized Ketoprofen-loaded novel proniosomal formulation for periodontitis: in vitro characterization and in vivo pharmacodynamic evaluation. AAPS PharmSciTech. 2017;18(5):1863–80. https://doi.org/10.1208/s12249-016-0665-1.CrossRefPubMedGoogle Scholar
- 40.Rarokar NR, Saoji SD, Raut NA, Taksande JB, Khedekar PB, Dave VS. Nanostructured cubosomes in a thermoresponsive depot system: an alternative approach for the controlled delivery of Docetaxel. AAPS PharmSciTech. 2016;17(2):436–45. https://doi.org/10.1208/s12249-015-0369-y.CrossRefPubMedGoogle Scholar
- 43.Beg S, Sandhu PS, Batra RS, Khurana RK, Singh B. QbD-based systematic development of novel optimized solid self-nanoemulsifying drug delivery systems (SNEDDS) of Lovastatin with enhanced biopharmaceutical performance. Drug Deliv. 2015;22(6):765–84. https://doi.org/10.3109/10717544.2014.900154.CrossRefPubMedGoogle Scholar
- 45.Noguchi H, Ojima Y, Yasui S. A practical variable selection for linear models. In: Lenz HJ, Schmid W, Wilrich PT, editors, Frontiers in statistical quality control. Springer; 2012. 10. p. 349–60.Google Scholar